Antipsychotic drugs and risk of idiopathic venous thromboembolism: A nested case-control study using the CPRD

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 11, 2014, Pages 1168-1175

  Ishiguro, Chieko ^a   Wang, Xi ^a   Li, Lin ^a   Jick, Susan ^a  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antipsychotic drugs; CPRD; Nested case control study; Pharmacoepidemiology; Venous thromboembolism

Indexed keywords

ESTROGEN; NEUROLEPTIC AGENT;

ADULT; AGE; BODY MASS; CASE CONTROL STUDY; CHEMICALLY INDUCED; CLASSIFICATION; COMORBIDITY; FEMALE; HUMAN; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RISK; RISK FACTOR; SEX DIFFERENCE; SMOKING; STATISTICAL MODEL; VENOUS THROMBOEMBOLISM;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CASE-CONTROL STUDIES; COMORBIDITY; ESTROGENS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PULMONARY EMBOLISM; RISK FACTORS; SEX FACTORS; SMOKING; VENOUS THROMBOEMBOLISM;

EID: 84920271672     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3699     Document Type: Article

References (29)

1. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356(9237): 1219-1223.
2. Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thromb Haemost 2002; 88(2): 205-209.
3. Liperoti R, Pedone C, Lapane K, Mor V, Bernabei R, Gambassi G. Venous thrombo-embolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005; 165: 2677-2682.
4. Lacut K, Le Gal G, Couturaud F, etal. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol 2007; 21: 643-650.
5. MHRA Public Assessment Report: the risk of venous thromboembolism associated with antipsychotics, June 2009 (accessed 18 July 2013) http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con049075.pdf.
6. Jönsson AK, Horváth-Puhó E, Hägg S, Pedersen L, Sorensen HT. Antipsychotics and risk of venous thromboembolism: a population-based case-control study. Clin Epidemiol 2009; 1: 19-26.
7. Kleijer BC, Heerdink ER, Egberts TC, Jansen PA, van Marum RJ. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. J Clin Psychopharmacol 2010; 30(5): 526-30. doi:10.1097/JCP.0b013e3181f0e87d.
8. Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010; 341: c4245. doi:10.1136/bmj.c4245.
9. Allenet B, Schmidlin S, Genty C, Bosson JL. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf 2012; 21(1): 42-8. doi:10.1002/pds.2210.
10. Schmedt N, Garbe E. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients with dementia. J Clin Psychopharmacol 2013 Dec; 33(6): 753-8. doi:10.1097/JCP.0b013e3182a412d5.
11. Zhang R, Dong L, Shao F, Tan X, Ying K. Antipsychotics and venous thromboembolism risk: a meta-analysis. Pharmacopsychiatry 2011; 44(5): 183-188. doi:10.1055/s-0031-1280814.
12. Chapelle C, Quenet S, Delavenne X, et al. Antipsychotics: a real or confounding risk factor for venous thromboembolism? Pharmacopsychiatry 2013; 46(1): 36-37. doi:10.1055/s-0032-1316347.
13. Tromeur C, Couturaud F. Antipsychotic drugs and venous thromboembolism. Thromb Res 2012; 130(suppl1): S29-31. doi:10.1016/j.thromres.2012.08.267.
14. Masopust J, Malý R, Vališ M. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry Clin Neurosci 2012; 66(7): 541-552. doi:10.1111/pcn.12001.
15. Shulman M, Jennifer Njoku I, Manu P. Thrombotic complications of treatment with antipsychotic drugs. Minerva Med 2013; 104(2): 175-184.
16. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766-768.
17. Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992; 1: 347-349.
18. Jick SS, Kaye JA, Vasilakis-scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23(5): 686-689.
19. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 2005; 3(8): 1611-1617.
20. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117(1): 93-102. Epub 2007 Dec 17.
21. Sim K, Su HC, Fujii S, et al. High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol 2009; 67(1): 110-7. doi:10.1111/j.1365-2125.2008.03304.x.
22. Janssen B, Weinmann S, Berger M, Gaebel W. Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull 2004; 30(4): 1023-1033.
23. Kroken RA, Johnsen E, Ruud T, Wentzel-Larsen T, Jørgensen HA. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry 2009; 9: 24. doi:10.1186/1471-244X-9-24.
24. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-35. Supplementary Appendix http://www.nejm.org/doi/suppl/10.1056/NEJMoa0806994/suppl_file/nejm_ray_225sa1.pdf (accessed 13 April 2014)
25. Boullin DJ, Woods HF, Grimes RP, Grahame-smith DG. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol 1975; 2: 29-35.
26. Orr MW, Boullin DJ. The relationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine. Br J Clin Pharmacol 1976; 3: 925-928.
27. Wallaschofski H, Eigenthaler M, Kiefer M, et al. Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychopharmacol 2003; 23: 479-483.
28. Axelsson S, Hägg S, Eriksson AC, Lindahl TL, Whiss PA. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin Exp Pharmacol Physiol 2007; 34(8): 775-780.
29. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68(1): 29-39.